Publications
A global phase II trial-in-progress with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer
American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)

January 23th-25th, 2020

A phase II clinical trial of the phosphatidylserine targeting antibody, bavituximab in combination with pembrolizumab in patients with advanced hepatocellular carcinoma
American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)

January 23th-25th, 2020

Working towards Precision Medicine for the Tumor Microenvironment
Society for Immunotherapy of Cancer (SITC)

November 6th-11th, 2019

SAFETY AND EXPOSURE OF BAVITUXIMAB IN PREVIOUSLY TREATED ASIAN AND NON-ASIAN NON-SMALL-CELL LUNG CANCER PATIENTS
Chinese Society of Clinical Oncology (CSCO)

September 11th, 2019